Nocturia and Aging: Diagnosis and Treatment

Advances in Chronic Kidney Disease

Volumn 17, Issue 4, 2010, Pages

  Boongird, Sarinya ^a   Shah, Nirav ^a   Nolin, Thomas D ^a   Unruh, Mark L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Aging; Chronic kidney disease; Health related quality of life; Nocturia; Nocturnal polyuria

Indexed keywords

ALFUZOSIN; BOTULINUM TOXIN; DARIFENACIN; DESMOPRESSIN; DIURETIC AGENT; DOXAZOSIN; DUTASTERIDE; FESOTERODINE; FINASTERIDE; MELATONIN; OXYBUTYNIN; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

AGING; BEDTIME DOSAGE; BEHAVIOR THERAPY; BLADDER CAPACITY; BLURRED VISION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIABETES INSIPIDUS; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; HYPONATREMIA; INSOMNIA; LIBIDO; NAUSEA; NOCTURIA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; POLYURIA; PRIAPISM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SLEEP DISORDER; URINE PH; URINE VOLUME; XEROSTOMIA;

AGED; AGED, 80 AND OVER; AGING; ANTIDIURETIC AGENTS; BEHAVIOR THERAPY; ENZYME INHIBITORS; HUMANS; KIDNEY DISEASES; MUSCARINIC ANTAGONISTS; NOCTURIA; POLYURIA; QUALITY OF LIFE; SLEEP DEPRIVATION; URINARY TRACT;

EID: 77953767115     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.04.004     Document Type: Review

References (81)

1. van Kerrebroeck P., Abrams P., Chaikin D., et al. The standardisation of terminology in nocturia: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 179-183
2. Mattsson S. Urinary incontinence and nocturia in healthy schoolchildren. Acta Paediatr 83 (1994) 950-954
3. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 50 (2006) 1306-1314 discussion 1314-1315
4. Tikkinen K.A., Tammela T.L., Huhtala H., et al. Is nocturia equally common among men and women? A population based study in Finland. J Urol 175 (2006) 596-600
5. Ouslander J.G., Nasr S.Z., Miller M., et al. Arginine vasopressin levels in nursing home residents with nighttime urinary incontinence. J Am Geriatr Soc 46 (1998) 1274-1279
6. Coyne K.S., Zhou Z., Bhattacharyya S.K., et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92 (2003) 948-954
7. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 84 (1999) 297-301
8. Kobelt G. Health-economic issues in nocturia. BJU Int 84 Suppl 1 (1999) 29-32
9. Guilleminault C., Lin C.M., Goncalves M.A., et al. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia. J Psychosom Res 56 (2004) 511-515
10. Agarwal R., Light R.P., Bills J.E., et al. Nocturia, nocturnal activity, and nondipping. Hypertension 54 (2009) 646-651
11. Tian Y., Serino R., and Verbalis J.G. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration. Am J Physiol Renal Physiol 287 (2004) F797-F805
12. Kikuchi Y. Participation of atrial natriuretic peptide (hANP) levels and arginine vasopressin (AVP) in aged persons with nocturia [in Japanese]. Nippon Hinyokika Gakkai Zasshi 86 (1995) 1651-1659
13. Ohashi M., Fujio N., and Nawata H. High plasma concentrations of human atrial natriuretic polypeptide in aged men. J Clin Endocrinol Metab 64 (1987) 81-85
14. Koopman M.G., Koomen G.C., Krediet R.T., et al. Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci (Lond) 77 (1989) 105-111
15. Asplund R., and Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 229 (1991) 131-134
16. Kawauchi A., Tanaka Y., Soh J., et al. Causes of nocturnal urinary frequency and reasons for its increase with age in healthy older men. J Urol 163 (2000) 81-84
17. Susset J.G., Servot-Viguier D., Lamy F., et al. Collagen in 155 human bladders. Invest Urol 16 (1978) 204-206
18. Ouslander J.G. Management of overactive bladder. N Engl J Med 350 (2004) 786-799
19. Pandit L., and Ouslander J.G. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 314 (1997) 228-231
20. Krol E., Rutkowski B., Czarniak P., et al. Early detection of chronic kidney disease: Results of the PolNef study. Am J Nephrol 29 (2009) 264-273
21. Agarwal R. Developing a self-administered CKD symptom assessment instrument. Nephrol Dial Transplant 25 (2010) 160-166
22. Conte G., Dal Canton A., Fuiano G., et al. Mechanism of impaired urinary concentration in chronic primary glomerulonephritis. Kidney Int 27 (1985) 792-798
23. Feinfeld D.A., and Danovitch G.M. Factors affecting urine volume in chronic renal failure. Am J Kidney Dis 10 (1987) 231-235
24. Fukuda M., Motokawa M., Miyagi S., et al. Polynocturia in chronic kidney disease is related to natriuresis rather than to water diuresis. Nephrol Dial Transplant 21 (2006) 2172-2177
25. Hsu C.Y., Iribarren C., McCulloch C.E., et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169 (2009) 342-350
26. McKeigue P.M., and Reynard J.M. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet 355 (2000) 486-488
27. Yalkut D., Lee L.Y., Grider J., et al. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med 128 (1996) 322-328
28. Kaynak H., Kaynak D., and Oztura I. Does frequency of nocturnal urination reflect the severity of sleep-disordered breathing?. J Sleep Res 13 (2004) 173-176
29. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
30. Kaye M. Aging, circadian weight change, and nocturia. Nephron Physiol 109 (2008) 11-18
31. Cugini P., Lucia P., Di Palma L., et al. Effect of aging on circadian rhythm of atrial natriuretic peptide, plasma renin activity, and plasma aldosterone. J Gerontol 47 (1992) B214-B219
32. Mock L.L., Parmelee P.A., Kutner N., et al. Content validation of symptom-specific nocturia quality-of-life instrument developed in men: Issues expressed by women, as well as men. Urology 72 (2008) 736-742
33. Abraham L., Hareendran A., Mills I.W., et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 63 (2004) 481-486
34. Bing M.H., Moller L.A., Jennum P., et al. Validity and reliability of a questionnaire for evaluating nocturia, nocturnal enuresis and sleep-interruptions in an elderly population. Eur Urol 49 (2006) 710-719
35. Buysse D.J., Reynolds III C.F., Monk T.H., et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 28 (1989) 193-213
36. Schatzl G., Temml C., Schmidbauer J., et al. Cross-sectional study of nocturia in both sexes: Analysis of a voluntary health screening project. Urology 56 (2000) 71-75
37. Bliwise D.L., Foley D.J., Vitiello M.V., et al. Nocturia and disturbed sleep in the elderly. Sleep Med 10 (2009) 540-548
38. Kobelt G., Borgstrom F., and Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 91 (2003) 190-195
39. Patel S.R., Ayas N.T., Malhotra M.R., et al. A prospective study of sleep duration and mortality risk in women. Sleep 27 (2004) 440-444
40. Boyle P., Robertson C., Mazzetta C., et al. The relationship between lower urinary tract symptoms and health status: The UREPIK study. BJU Int 92 (2003) 575-580
41. Pollak C.P., and Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 4 (1991) 204-210
42. Ransmayr G.N., Holliger S., Schletterer K., et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 70 (2008) 299-303
43. Goudsmit E., Neijmeijer-Leloux A., and Swaab D.F. The human hypothalamo-neurohypophyseal system in relation to development, aging and Alzheimer's disease. Prog Brain Res 93 (1992) 237-247 discussion 247-248
44. Sakakibara R., Uchiyama T., Liu Z., et al. Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients. Intern Med 44 (2005) 281-284
45. Tikkinen K.A., Johnson II T.M., Tammela T.L., et al. Nocturia frequency, bother, and quality of life: How often is too often? A population-based study in Finland. Eur Urol 57 (2010) 488-496
46. Van der Woude P.F., Goudsmit E., Wierda M., et al. No vasopressin cell loss in the human hypothalamus in aging and Alzheimer's disease. Neurobiol Aging 16 (1995) 11-18
47. Yoshimura K., Terada N., Matsui Y., et al. Prevalence of and risk factors for nocturia: Analysis of a health screening program. Int J Urol 11 (2004) 282-287
48. Tikkinen K.A., Auvinen A., Johnson II T.M., et al. A systematic evaluation of factors associated with nocturia-The population-based FINNO study. Am J Epidemiol 170 (2009) 361-368
49. Asplund R. Pharmacotherapy for nocturia in the elderly patient. Drugs Aging 24 (2007) 325-343
50. Darowski A., Chambers S.A., and Chambers D.J. Antidepressants and falls in the elderly. Drugs Aging 26 (2009) 381-394
51. Asplund R., Johansson S., Henriksson S., et al. Nocturia, depression and antidepressant medication. BJU Int 95 (2005) 820-823
52. Cardozo L., and Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 60 (2002) 64-71 discussion 71
53. Movig K.L., Leufkens H.G., Belitser S.V., et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 11 (2002) 271-279
54. Shiri R., Hakama M., Hakkinen J., et al. The effects of lifestyle factors on the incidence of nocturia. J Urol 180 (2008) 2059-2062
55. Aslan E., Komurcu N., Beji N.K., et al. Bladder training and Kegel exercises for women with urinary complaints living in a rest home. Gerontology 54 (2008) 224-231
56. Margel D., Shochat T., Getzler O., et al. Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology 67 (2006) 974-977
57. Drake M.J., Mills I.W., and Noble J.G. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 171 (2004) 1199-1202
58. Vaughan C.P., Endeshaw Y., Nagamia Z., et al. A multicomponent behavioural and drug intervention for nocturia in elderly men: Rationale and pilot results. BJU Int 104 (2009) 69-74
59. Appell R.A., and Sand P.K. Nocturia: Etiology, diagnosis, and treatment. Neurourol Urodyn 27 (2008) 34-39
60. Simon H.U., and Malhotra B. The pharmacokinetic profile of fesoterodine: Similarities and differences to tolterodine. Swiss Med Wkly 139 (2009) 146-151
61. Michel M.C. Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9 (2008) 1787-1796
62. Salvatore S., Serati M., and Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother 9 (2008) 1249-1255
63. Wolzt M., Fabrizii V., Dorner G.T., et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: An open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 54 (1998) 367-373
64. Wilde M.I., and McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 52 (1996) 883-898
65. Huskey S.W., Dean D.C., Miller R.R., et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 23 (1995) 1126-1135
66. Steiner J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30 (1996) 16-27
67. Doroshyenko O., and Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet 48 (2009) 281-302
68. Biastre K., and Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 43 (2009) 283-295
69. Rembratt A., Graugaard-Jensen C., Senderovitz T., et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 60 (2004) 397-402
70. Agerso H., Seiding Larsen L., Riis A., et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 58 (2004) 352-358
71. Lose G., Mattiasson A., Walter S., et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 172 (2004) 1021-1025
72. Rembratt A., Riis A., and Norgaard J.P. Desmopressin treatment in nocturia: An analysis of risk factors for hyponatremia. Neurourol Urodyn 25 (2006) 105-109
73. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: A systematic review and meta-analysis. Neurourol Urodyn 23 (2004) 302-305
74. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
75. Johnson II T.M., Jones K., Williford W.O., et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: Secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 170 (2003) 145-148
76. Robinson D., Cardozo L., Terpstra G., et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 100 (2007) 840-845
77. Johnson II T.M., Burrows P.K., Kusek J.W., et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 178 (2007) 2045-2050 discussion 2050-2051
78. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
79. Hassouna M.M., Siegel S.W., Nyeholt A.A., et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: A multicenter study on efficacy and safety. J Urol 163 (2000) 1849-1854
80. Kessler T.M., Danuser H., Schumacher M., et al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 24 (2005) 231-236
81. Fowler Jr. F.J., Wennberg J.E., Timothy R.P., et al. Symptom status and quality of life following prostatectomy. JAMA 259 (1988) 3018-3022